LacoutureME, SibaudV, GerberPA, et al.; ESMO Guidelines Committee. Electronic address:clinicalguidelines@esmo.org. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines☆. Ann Oncol, 2021; 32(2):157–170; doi: 10.1016/j.annonc.2020.11.005
2.
MillerKK, GorceyL, McLellanBN. Chemotherapy-induced hand-foot syndrome and nail changes: A review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol, 2014; 71(4):787–794; doi: 10.1016/j.jaad.2014.03.019
3.
LiJ, GuJ. Hand-foot skin reaction with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: A systematic review and meta-analysis. Crit Rev Oncol Hematol, 2017; 119:50–58; doi: 10.1016/j.critrevonc.2017.09.016
4.
KwakmanJJM, ElshotYS, PuntCJA, et al.Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev, 2020; 14(1):442; doi: 10.4081/oncol.2020.442
5.
McLellanB, KerrH. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther, 2011; 24(4):396–400; doi: 10.1111/j.1529-8019.2011.01435.x
LipworthAD, RobertC, ZhuAX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): Focus on sorafenib and sunitinib. Oncology, 2009; 77(5):257–271; doi: 10.1159/000258880
10.
LanT-C, TsouP-H, TamK-W, et al.Effect of urea cream on hand-foot syndrome in patients receiving chemotherapy: A meta-analysis. Cancer Nurs, 2022; 45(5):378–386; doi: 10.1097/NCC.0000000000001008
11.
PandyJGP, FrancoPIG, LiRK. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: A meta-analysis of randomized controlled trials. Support Care Cancer, 2022; 30(11):8655–8666; doi: 10.1007/s00520-022-07175-3
12.
SanthoshA, SharmaA, BakhshiS, et al.; D-TORCH Trial Investigators. Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: A double-blind randomized controlled trial. J Clin Oncol, 2024; 42(15):1821–1829; doi: 10.1200/JCO.23.01730
13.
ChenM, ZhangL, WangQ, et al.Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: A systematic review. PLoS One, 2013; 8(8):e72245; doi: 10.1371/journal.pone.0072245
14.
McLellanB, CiardielloF, LacoutureME, et al.Regorafenib-associated hand-foot skin reaction: Practical advice on diagnosis, prevention, and management. Ann Oncol, 2015; 26(10):2017–2026; doi: 10.1093/annonc/mdv244
15.
MeadowsKL, RushingC, HoneycuttW, et al.Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: A pilot study. Support Care Cancer, 2015; 23(5):1311–1319; doi: 10.1007/s00520-014-2465-z
16.
LatifyanS, GenotMT, FernezB, et al.Use of low-level laser therapy (LLLT) or photobiomodulation (PBM) for the management of the hand-foot syndrome (HSF) or palmo-plantar erythrodysesthesia (PPED) associated with cancer therapy. Support Care Cancer, 2020; 28(7):3287–3290; doi: 10.1007/s00520-019-05099-z
17.
WongkraisriC, ChusuwanrakK, LaocharoenkeatA, et al.Randomized controlled trial on the efficacy of topical urea-based cream in preventing capecitabine-associated hand-foot syndrome. BMC Cancer, 2025; 25(1):275; doi: 10.1186/s12885-025-13684-1
18.
DegenA, AlterM, SchenckF, et al.The hand-foot-syndrome associated with medical tumor therapy—Classification and management. J Dtsch Dermatol Ges, 2010; 8(9):652–661; doi: 10.1111/j.1610-0387.2010.07449.x
